Paul Thompson

Paul Thompson

Company: Mission Therapeutics

Job title: CSO


Novel DUB Inhibitor Platform Addressing Protein Homeostasis 9:00 am

Mission has developed a world-leading potent and selective DUB inhibitor library Selective tools provide best method for elucidating DUB enzyme regulation of disease pathophysiology USP30 inhibitors exemplify progression from hit to candidate, with more DUB target programs to followRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.